18 May 2025
UnitedHealth Group (UNH) – Oversold & Attracting Insider Confidence
UNH has recently drawn attention after its stock price dropped over 50% since mid-April 2025. Putting aside the fundamental and media noise, the technical analysis shows that the stock is heavily oversold.
Last Friday, the stock rebounded over 6%, possibly driven by a strong show of confidence from insiders. Newly reinstated CEO Stephen Hemsley purchased approximately $25 million worth of UNH shares (86,700 shares at an average of $288.18). CFO John Rex also acquired $5 million, with directors Timothy Flynn and Kristen Gil making significant purchases as well.
From a price action standpoint, the current level appears attractive for a Dollar-Cost Averaging (DCA) approach. However, I'm personally eyeing a potential deeper discount entry zone between $200–$220, which would offer an even more compelling long-term risk-reward setup.
Strategy: Start small with DCA at current levels, but be patient for deeper dips for larger entries.
UnitedHealth Group (UNH) – Oversold & Attracting Insider Confidence
UNH has recently drawn attention after its stock price dropped over 50% since mid-April 2025. Putting aside the fundamental and media noise, the technical analysis shows that the stock is heavily oversold.
Last Friday, the stock rebounded over 6%, possibly driven by a strong show of confidence from insiders. Newly reinstated CEO Stephen Hemsley purchased approximately $25 million worth of UNH shares (86,700 shares at an average of $288.18). CFO John Rex also acquired $5 million, with directors Timothy Flynn and Kristen Gil making significant purchases as well.
From a price action standpoint, the current level appears attractive for a Dollar-Cost Averaging (DCA) approach. However, I'm personally eyeing a potential deeper discount entry zone between $200–$220, which would offer an even more compelling long-term risk-reward setup.
Strategy: Start small with DCA at current levels, but be patient for deeper dips for larger entries.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。